How can we improve our understanding of the progression of myeloma?

Irene Ghobrial, MD of the Dana-Farber Cancer Institute (DFCI), Boston, MA, discusses the progression of multiple myeloma (MM), which comes from precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. It is not known, however, which patients will progress. +watch video

Recent Posts

See All

Honoring a decade of Standing Up To Cancer

On September 7, Stand Up To Cancer’s (SU2C) telecast shared inspiring stories of hope, perseverance, and groundbreaking cancer research to a worldwide audience. +read more

DFCI Logo Lens Stacked PNG_edited.png
CPOP_R02.png

© 2018 Dana-Farber Cancer Institute |  Terms of Use  |   Privacy Policy